Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

被引：1
|
作者：
Joseph, Nisha [1 ]
Gupta, Vikas A. [2 ]
Hofmeister, Craig C. [3 ]
Gleason, Charise [1 ]
Heffner, Leonard [3 ]
Boise, Lawrence H. [4 ,5 ]
Kaufman, Jonathan L. [3 ]
Dhodapkar, Madhav V. [5 ]
Lonial, Sagar [3 ]
Nooka, Ajay K. [3 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[4] Emory Univ, Div BMT, Atlanta, GA 30322 USA
[5] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119895
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3294
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    [J]. BLOOD, 2017, 130
  • [2] Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.
    Ailawadhi, Sikander
    Lee, Hans Chulhee
    Omel, Jim
    Toomey, Kathleen
    Hardin, James W.
    Gasparetto, Cristina
    Jagannath, Sundar
    Rifkin, Robert M.
    Durie, Brian G.
    Narang, Mohit
    Terebelo, Howard R.
    Wagner, Lynne, I
    Dhalla, Mazaher
    He, Mia
    Srinivasan, Shankar
    Joshi, Prashant Ramesh
    Robinson, Suzanne
    Abonour, Rafat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
    Nooka, Ajay K.
    Langston, Amelia A.
    Waller, Edmund K.
    Heffner, Leonard T.
    Gleason, Charise
    Muppidi, Samatha
    Watson, Melanie
    Casbourne, Daniela
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Gleason, Charise
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Steuer, Conor E.
    Kumar, Mukesh
    Casbourne, Daniela
    Langston, Amelia A.
    Watson, Melanie
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    [J]. BMC CANCER, 2024, 24 (01)
  • [6] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    [J]. BLOOD, 2010, 116 (05) : 679 - 686
  • [7] Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma
    Bici, Anisa
    Pianko, Matthew J.
    Nachar, Victoria R.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 407 - 414
  • [8] Incidence and risk factors for bacterial infection in newly diagnosed multiple myeloma patients undergoing treatment with bortezomib, lenalidomide, and dexamethasone (RVD).
    Pianko, Matthew James
    Bici, Anisa
    Nachar, Victoria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [10] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    [J]. Blood Cancer Journal, 13
12345